Avidity Partners Management LP Arrowhead Pharmaceuticals, Inc. Transaction History

Avidity Partners Management LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$21.2 - $31.03 $7.42 Million - $10.9 Million	-349,897 Reduced 32.89%	714,000 $21.8 Million
Q3 2023 Nov 14, 2023	BUY	$26.2 - $36.08 $3.64 Million - $5.01 Million	138,897 Added 15.02%	1,063,897 $28.6 Million
Q2 2023 Aug 14, 2023	SELL	$25.16 - $41.38 $20.5 Million - $33.8 Million	-816,300 Reduced 46.88%	925,000 $33 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $8.67 Million - $14.1 Million	366,300 Added 26.64%	1,741,300 $44.2 Million
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $3.35 Million - $4.85 Million	119,626 Added 9.53%	1,375,000 $55.8 Million

Q3 2022 Nov 14, 2022	SELL	$29.63 - $48.31 $5.44 Million - $8.87 Million	-183,625 Reduced 12.76%	1,255,374 $41.5 Million
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $13.5 Million - $24.5 Million	483,999 Added 50.68%	1,438,999 $50.7 Million
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $3.17 Million - $5.6 Million	80,000 Added 9.14%	955,000 $43.9 Million
Q4 2021 Feb 14, 2022	BUY	$58.09 - $82.51 $11.7 Million - $16.6 Million	201,300 Added 29.88%	875,000 $58 Million
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $33.3 Million - $48.4 Million	569,700 Added 547.79%	673,700 $42.1 Million
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $6.46 Million - $9.39 Million	104,000 New	104,000 $8.61 Million

296

88.5M

905K

387K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.71B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.